GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Regenix Group PLC (LSE:TRX) » Definitions » Total Payout Ratio

Tissue Regenix Group (LSE:TRX) Total Payout Ratio : 0.00 (As of Jun. 04, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Tissue Regenix Group Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Tissue Regenix Group's current Total Payout Ratio is 0.00.


Tissue Regenix Group Total Payout Ratio Historical Data

The historical data trend for Tissue Regenix Group's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Regenix Group Total Payout Ratio Chart

Tissue Regenix Group Annual Data
Trend Jan14 Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.42 - - 0.04

Tissue Regenix Group Semi-Annual Data
Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 - - -

Competitive Comparison of Tissue Regenix Group's Total Payout Ratio

For the Biotechnology subindustry, Tissue Regenix Group's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tissue Regenix Group's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's Total Payout Ratio falls into.



Tissue Regenix Group Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Tissue Regenix Group's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0.058 + 0) / -1.319
=0.04

Tissue Regenix Group's Total Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -0.59
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tissue Regenix Group Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Tissue Regenix Group's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Tissue Regenix Group (LSE:TRX) Business Description

Traded in Other Exchanges
Address
Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.